106 related articles for article (PubMed ID: 25529769)
21. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
22. Outcome of patients with myelodysplastic syndromes: experience from a single institution in South Australia.
Hui CH; Horvath N; Lewis I; To LB; Szabo F
Intern Med J; 2008 Nov; 38(11):824-8. PubMed ID: 18284457
[TBL] [Abstract][Full Text] [Related]
23. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
[TBL] [Abstract][Full Text] [Related]
24. Tea consumption and risk of cancer of the colon and rectum.
Cerhan JR; Putnam SD; Bianchi GD; Parker AS; Lynch CF; Cantor KP
Nutr Cancer; 2001; 41(1-2):33-40. PubMed ID: 12094626
[TBL] [Abstract][Full Text] [Related]
25. Bone marrow blasts level predicts prognosis in patients with refractory cytopenia with multilineage dysplasia.
Wang H; Wang XQ; Xu XP; Lin GW
Eur J Haematol; 2009 Dec; 83(6):550-8. PubMed ID: 19737310
[TBL] [Abstract][Full Text] [Related]
26. [A case-control study on tea consumption and the risk of lung cancer].
Xu X; Cai L
Wei Sheng Yan Jiu; 2013 Mar; 42(2):211-6. PubMed ID: 23654095
[TBL] [Abstract][Full Text] [Related]
27. The long term risk of myelodysplastic syndromes among anemia patients: a population-based study.
Meytes D; Chodick G; Shalev V; Porath A
Leuk Res; 2012 Mar; 36(3):327-30. PubMed ID: 22142797
[TBL] [Abstract][Full Text] [Related]
28. Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes.
Chu SC; Wang TF; Li CC; Kao RH; Li DK; Su YC; Wells DA; Loken MR
Leuk Res; 2011 Jul; 35(7):868-73. PubMed ID: 21397943
[TBL] [Abstract][Full Text] [Related]
29. [Re-evaluation of classification of myelodysplastic syndromes with low percentage bone marrow blasts].
Yu MH; Xu ZF; Li L; Nie L; Liu L; Zhang Y; Qin TJ; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):3-7. PubMed ID: 19563026
[TBL] [Abstract][Full Text] [Related]
30. Tea consumption and ovarian cancer risk: a case-control study in China.
Zhang M; Binns CW; Lee AH
Cancer Epidemiol Biomarkers Prev; 2002 Aug; 11(8):713-8. PubMed ID: 12163323
[TBL] [Abstract][Full Text] [Related]
31. Smoking and alcohol and subsequent risk of myelodysplastic syndromes in Japan: the Japan Public Health Centre-based Prospective Study.
Ugai T; Matsuo K; Sawada N; Iwasaki M; Yamaji T; Shimazu T; Sasazuki S; Inoue M; Kanda Y; Tsugane S;
Br J Haematol; 2017 Sep; 178(5):747-755. PubMed ID: 28714213
[TBL] [Abstract][Full Text] [Related]
32. Myelodysplastic syndromes: a community hospital-based study of prognostic factors and International Prognostic Scoring System.
Mirza I; Garzón R; Burns J; Edwards L; Fernandez-Cymering C; Kloss R
Conn Med; 2001 Aug; 65(8):455-63. PubMed ID: 11550445
[TBL] [Abstract][Full Text] [Related]
33. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I
Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460
[TBL] [Abstract][Full Text] [Related]
34. Case-control study of green tea consumption and the risk of endometrial endometrioid adenocarcinoma.
Kakuta Y; Nakaya N; Nagase S; Fujita M; Koizumi T; Okamura C; Niikura H; Ohmori K; Kuriyama S; Tase T; Ito K; Minami Y; Yaegashi N; Tsuji I
Cancer Causes Control; 2009 Jul; 20(5):617-24. PubMed ID: 19067194
[TBL] [Abstract][Full Text] [Related]
35. Risk factors for myelodysplastic syndromes: a case-control study in Greece.
Dalamaga M; Petridou E; Cook FE; Trichopoulos D
Cancer Causes Control; 2002 Sep; 13(7):603-8. PubMed ID: 12296507
[TBL] [Abstract][Full Text] [Related]
36. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001.
Mauritzson N; Albin M; Rylander L; Billström R; Ahlgren T; Mikoczy Z; Björk J; Strömberg U; Nilsson PG; Mitelman F; Hagmar L; Johansson B
Leukemia; 2002 Dec; 16(12):2366-78. PubMed ID: 12454741
[TBL] [Abstract][Full Text] [Related]
37. Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes.
Ohyashiki JH; Iwama H; Yahata N; Ando K; Hayashi S; Shay JW; Ohyashiki K
Clin Cancer Res; 1999 May; 5(5):1155-60. PubMed ID: 10353751
[TBL] [Abstract][Full Text] [Related]
38. Cytogenetic characteristics and prognosis analysis in 231 myelodysplastic syndrome patients from a single institution.
Jung SW; Lee SY; Jekarl DW; Kim M; Lim J; Kim Y; Han K; Kim YJ; Cho SG; Song J
Leuk Res; 2011 Jun; 35(6):735-40. PubMed ID: 21146871
[TBL] [Abstract][Full Text] [Related]
39. [Expression of differentiation antigens on bone marrow myeloid cells of the patients with myelodysplastic syndromes and its clinical significances].
Li LJ; Fu R; Wang HQ; Yue LZ; Liu H; Wang J; Wang HL; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Song J; Wu YH; Xing LM; Guan J; Shao ZH
Zhonghua Yi Xue Za Zhi; 2010 Mar; 90(10):672-7. PubMed ID: 20450725
[TBL] [Abstract][Full Text] [Related]
40. Risk factors for de novo and therapy-related myelodysplastic syndromes (MDS).
Yarosh R; Roesler MA; Murray T; Cioc A; Hirsch B; Nguyen P; Warlick E; Poynter JN
Cancer Causes Control; 2021 Mar; 32(3):241-250. PubMed ID: 33392905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
